A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

To join this study, you generally need to have a solid tumour that has spread or is advanced, and your tumour must have a specific genetic change called an MTAP deletion. This genetic change would need to be found in a sample of your tumour tissue. You would also typically have tried standard treatments for your cancer, and these treatments are no longer working, or you can't have them for other reasons.

There are also some important health checks you'd need to meet. For example, your general health and how well you can do daily activities would be reviewed; doctors use a scale where being a 0 or 1 means you're generally quite active. Your blood clotting and organ functions (like liver and kidney) would also need to be within healthy ranges.

However, you wouldn't be able to join if you've already had certain types of cancer treatment (PRMT5 or MAT2A inhibitors). If your cancer has spread to your brain, you might not be eligible unless it's been successfully treated and stable for a while without needing strong steroids. Also, if you have certain stomach or gut problems that might stop you from absorbing medicines properly or swallowing pills, you might not be able to take part.

If you join this study, you will receive the study medicine, BMS-986504, either on its own or in combination with other anti-cancer drugs. The study is divided into parts; initially, some people will receive BMS-986504 by itself, and others will receive it alongside other treatments. The specific combination of drugs and how they are given will depend on which part of the study you join and your type of cancer. This study is described as 'open-label,' meaning both you and your study doctor will know which treatment you are receiving.

You will have regular visits to the hospital or clinic for assessments, which will include physical exams, blood tests, and scans to monitor your health and how the treatment is working. These tests help doctors check the safety of the medication and any effects it has on your tumour. The exact number of visits and tests will be detailed by the study team. You will continue treatment for as long as it is benefiting you and you are tolerating it well. Following your treatment period, there will be follow-up visits to continue monitoring your health and the long-term effects.